Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.
Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.
Caribou Biosciences (Nasdaq: CRBU) reported second quarter 2026 results and key updates on its allogeneic CAR-T pipeline. In the ANTLER phase 1 trial, vispacabtagene regedleucel (vispa-cel) in second-line large B cell lymphoma showed an 82% overall response rate, 67% complete response rate, 17.1-month median progression-free survival, and a generally well-tolerated safety profile in 27 optimized patients treated with a single 80 million cell dose.
In the CaMMouflage phase 1 trial, CB-011 in 12 BCMA-naïve relapsed/refractory multiple myeloma patients at the 450 million cell dose achieved a 92% overall response rate, 83% ≥CR rate, and 91% MRD negativity in evaluable patients. Q2 2026 licensing and other revenue was $1.5 million, R&D expenses $18.9 million, G&A expenses $7.9 million, and GAAP net loss $24.3 million ($0.24 per share). Caribou ended June 30, 2026 with $113.8 million in cash, cash equivalents, and marketable securities and expects this to fund operations into the end of 2027, including CB-011 dose expansion and ANTLER-3 start-up activities.
Caribou Biosciences (Nasdaq: CRBU) announced that president and CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET.
Investors can access a webcast via the Events page on Caribou’s website, where replays will remain available for at least 30 days.
Caribou Biosciences (Nasdaq: CRBU) reported long-term ANTLER phase 1 data for vispa-cel, an allogeneic CD19 CAR-T, in second-line large B cell lymphoma (2L LBCL). In 27 optimized-dose patients, a single 80-million-cell infusion achieved 82% ORR, 67% CR, and 17.1-month median PFS.
The safety profile showed no graft-versus-host disease, no ≥grade 3 ICANS, one (4%) ≥grade 3 CRS, and serious infections and cytopenias in some patients. Caribou outlined the ANTLER-3 pivotal phase 3 trial, enrolling ~250 CD19-naïve 2L LBCL patients versus standard regimens, with PFS as the primary endpoint.
Caribou Biosciences (Nasdaq: CRBU) reported longer follow up data from the phase 1 CaMMouflage trial of CB-011, an off-the-shelf BCMA-targeted CAR-T for relapsed/refractory multiple myeloma.
At the recommended dose, a single infusion showed high response rates, deep MRD-negative remissions, and a manageable safety profile, plus a detailed case after prior BCMA CAR-T.
Caribou Biosciences (Nasdaq: CRBU) announced that president and CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 2:35 p.m. ET in New York.
The live and archived webcasts will be accessible via the Events page on Caribou’s website for at least 30 days.
Caribou Biosciences (Nasdaq: CRBU) announced that its management team will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026 at 12:30 p.m. ET in New York.
A live webcast and replay will be available for at least 30 days on the Events page of Caribou’s website.
Caribou Biosciences (Nasdaq: CRBU) will feature its allogeneic CAR-T programs vispa-cel and CB-011 in oral presentations at the 2026 European Hematology Association Annual Meeting in Stockholm, June 11-14, 2026.
Presentations cover ANTLER and CaMMouflage phase 1 trials in lymphoma and multiple myeloma.
Caribou Biosciences (Nasdaq: CRBU) reported Q1 2026 results and clinical updates on May 7, 2026. Key items: FDA alignment on the pivotal ANTLER-3 vispa-cel trial design; RMAT designation for CB-011 with strong early response rates; Q1 cash of $118.6M and cash runway into 2H 2027.
Company expects longer follow-up data for vispa-cel and CB-011 in 2026 and is exploring funding options for the vispa-cel pivotal trial.
Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz, PhD, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on May 13, 2026 at 8:40am PT in Las Vegas.
Webcast details and replay access are available via the company Events page; webcasts remain available for at least 30 days after the event.
Caribou Biosciences (Nasdaq: CRBU) announced the FDA granted RMAT designation to CB-011, an allogeneic anti-BCMA CAR-T for relapsed or refractory multiple myeloma.
RMAT follows promising CaMMouflage phase 1 dose‑escalation data: 92% ORR, 75% ≥CR, and 91% MRD negativity in 12 BCMA‑naïve patients at the recommended dose for expansion; dose expansion and additional 2026 data planned.